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Table 1. Factors Predictive of Neutrophil and Platelet Engraftment in
Multivariate Analysis of Graft/Recipient Characteristics
Multivariate Model
Neutrophil
engraftment
(p-value)
Platelet
engraftment
(p-value)
Pre-cryopreservation CD341 (0.0046) Recipient ethnicity
(0.0052)
Recipient CMV
(0.0138)
TNC (0.0173)
CFU (0.0337) CFU (0.0324)
Unit Sex (0.0393)
Post-thaw CFU (\0.0001) CFU (\0.0001)
CD34 (0.0013) HLA match (0.0117)
HLA match
(0.0065)
Recipient ethnicity
(0.0135)
Overall Post thaw CFU
(\0.0001)
Recipient ethnicity
(0.0063)
Unit Sex (0.0131) Post thaw CFU (0.002)
HLA match (0.0186)
Post thaw CD34 (0.02)
AXP Stem Cell Recovery
Volume
(mL)
Mean Post-
Processing
TNC
(108)
TNC
Percent
Recovery
(%)
Mean Post-
Processing
MNC
(108)
MNC
Percent
Recovery
(%)
Mean 72.93 9.94 96.19 4.05 98.65
Standard
Deviation
18.10 4.43 11.87 1.59 9.16
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STEM CELL RECOVERY FOLLOWING IMPLEMENTATION OF AN AUTO-
MATED CORD BLOOD PROCESSING SYSTEM IN A HIGH VOLUME LABO-
RATORY
Rosenthal, J.1, Brown, H.L.2, Harris, D.T.3 1City of Hope, Duarte, CA;
2CBR Systems, Inc., San Bruno, CA; 3University of Arizona, Tucson,
AZ.
Background: Many cord blood unit (CBU) processing facilities
are transitioning to automated systems to standardize methods
and decrease human error. The AutoXpress Platform (AXP)
is an automated, functionally closed, sterile CBUprocessing system.
When placedwithin the AXP device and centrifuged, whole blood is
separated into composite cell populations and the TNC fraction is
separated and automatically delivered into a blow-molded freezing
bag at a uniform volume of 21 mL.Objective:This study evaluated
the use of the AXP system in a directed donation family cord blood
bank, targeted at producing consistently high TNC and MNC re-
covery rates regardless of variability in collection volume.
Methods: CBU were collected between 12/5/2006 and 2/24/2007
from 1414 consenting mothers who elected to preserve and bank
CBU at Cord Blood Registry (CBR). Collection kits were provided
at enrollment, and after delivery, cord blood was collected from the
umbilical cord and transported to CBR’s processing facility in Tuc-
son, Arizona. During the study period, CBU arriving at the CBR
laboratory were allocated to either ficoll or AXP processing based
on the volume, age, and the degree of clotting. Units processed us-
ing AXP had a volume of 40–130 mL, an age of less than 48 hours
since collection, and a clotting score of 0 to 21 (based on an internal
scale). TNC andMNCwere measured both pre- and post-process-
ing, using the Sysmex analyzer. Results:The mean age of CBU ar-
riving at the laboratory was 23.59 hours, and the mean collection
volume was 72.93 mL (618.10 mL). The mean TNC count post-
processing was 9.94  108, the TNC percent recovery was
96.19%, and the mean MNC percent recovery was 98.65%. Con-
clusions: AXP automated processing provides consistently high
TNC and MNC recovery rates, which has important implications
for stem cell dose if the sample is used in transplant. Because limited
cell dose is frequently cited as an obstacle to CBU transplantation,
processing results could impact the usability of each sample. Be-
cause family cord blood banks process all samples, regardless of col-
lection volume, percent recovery becomes particularly important in
evaluating the differences between processing centers. The AXP
system yields the highest published cell recovery rate to date and
can be easily integrated into a CBU processing center such that it
decreases the labor and time required for CBU processing while
maintaining MNC recovery of greater than 98%.109
IgH GENE REARRANGEMENTS IN PBPC MONONUCLEAR CELLS DOES
NOT INFLUENCE SURVIVAL OR RELAPSE FOLLOWING AUTOLOGOUS
TRANSPLANTATION FOR B-CELL LYMPHOPROLIFERATIVE DISEASES
Ho, J.1, Yang, L.2, Benihashemi, B.1, Martin, L.2, Halpenny, M.2,
McDiarmid, S.1, Huebsch, L.1, Sabloff, M.1, Atkins, H.1, Bence-
Bruckler, I.1, Giulivi, A.2, Allan, D.1 1University of Ottawa, Ottawa,
ON, Canada; 2Canadian Blood Services, Ottawa, ON, Canada.
Background: Relapsed disease remains a major obstacle follow-
ing autologous hematopoietic stem cell transplantation (HSCT) for
non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM).
Studies regarding the role of residual tumour cells collected in au-
tografts in earlier relapse and reduced survival have been inconclu-
sive. The impact of residual disease detected by sensitive molecular
methods in autologous PBPCs remains uncertain and is addressed
in this study. Methods: Patients undergoing autologous HSCT
forNHL andMMat our institution between June 2001 and January
2006 were enrolled (n 5 158). Aliquots of freshly collected PBPC
collections were assessed for the presence of clonal IgH gene rear-
rangements using qualitative semi-nested PCR. Patients with de-
tectable clonal IgH gene rearrangements were designated
‘‘positive’’ and compared with ‘‘negative’’ patients without detect-
able IgH gene rearrangements. Survival, progression-free survival,
and time to next treatment were determined for all patients. All out-
comes were compared using the method of Kaplan and Meier.
Results: In comparison to patients with ‘‘positive’’ PBPC grafts,
patients ‘‘negative’’ for detectable disease had no improvement in
overall survival forMM (p5 0.91) and forNHL (p5 0.82). Further
analysis based on tissue histology in patients with NHL revealed no
significant difference in overall survival between patients with ‘‘pos-
itive’’ grafts comparedwith ‘‘negative’’ PBPC collections (aggressive
histologyNHL, p5 0.74; indolentNHL, p5 0.29). There was also
no significant improvement in progression-free survival among pa-
tients with NHL (p 5 0.85) or MM (p 5 0.91). Conclusion: The
use of autologous PBPCs ‘‘negative’’ for contaminating tumour cells
does not lead to improved overall survival inMMorNHL. Further-
more, the absence of detectable clonal IgH rearrangements using
sensitive PCR did not correlate with a reduction in progression-
free survival. Our results suggest that disease relapse cannot be ad-
equately explained by the reinfusion of PBPCs containing residual
tumour cells. It is possible that high dose chemotherapy regimens
used in autologous HSCT are not sufficiently eliminating residual
tumour burden in some patients, including those with ‘‘negative’’
PBPC collections. Taken together, our results suggest that strate-
gies aimed at removing tumour cells from autologous PBPC grafts
in patients with MM and NHL may have marginal benefit.110
ENHANCED NATURAL KILLER (NK) AND NK T CELL ACTIVATION, EX-
PANSION AND CYTOKINE PROTEIN PRODUCTION FOLLOWING EX-
VIVO ENGINEERING (EvE) OF PREVIOUSLY CRYOPRESERVED CORD
BLOOD (CB): POTENTIAL FOR CB NK AND NK T CELLS IN ADOPTIVE
CELLULAR IMMUNOTHERAPY (ACI)
Ayello, J., Sugarman, E., Day, N., Hochberg, J., Mar, B., Cairo, E., van
de Ven, C., Cairo, M.S. Columbia University, New York, NY.
CB is limited by the absence of available donor effector cells fol-
lowing UCBT.We demonstrated the immaturity of CB by reduced
